Bioventus
BVS
157 hedge funds and large institutions have $466M invested in Bioventus in 2026 Q1 according to their latest regulatory filings, with 30 funds opening new positions, 57 increasing their positions, 46 reducing their positions, and 18 closing their positions.
447% more call options, than puts
Call options by funds: $1.95M | Put options by funds: $357K
67% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 18
25% more capital invested
Capital invested by funds: $373M → $466M (+$93.1M)
24% more repeat investments, than reductions
Existing positions increased: 57 | Existing positions reduced: 46
6% more funds holding
Funds holding: 148 → 157 (+9)
0.86% more ownership
Funds ownership: 74.93% → 75.79% (+0.86%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HIM
Hillsdale Investment Management
Toronto,
Ontario, Canada
|
+$3.36M |
| 2 |
ECM
Engine Capital Management
New York
|
+$2.64M |
| 3 |
RA
Royce & Associates
New York
|
+$2.43M |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
+$2.32M |
| 5 |
WCM
Wedge Capital Management
Charlotte,
North Carolina
|
+$2.03M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCA
Buckley Capital Advisors
Miami Beach,
Florida
|
-$2.71M |
| 2 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$2.65M |
| 3 |
EP
Eversept Partners
New York
|
-$2.62M |
| 4 |
American Century Companies
Kansas City,
Missouri
|
-$1.91M |
| 5 |
Jane Street
New York
|
-$1.72M |
BVS Hedge Fund Activity: Q1 2026 in Review
157 of the 8,180 institutional investors tracked by Wall St. Rank reported a position in Bioventus (BVS) for Q1 2026, worth a combined $466M — up 25% from $373M a quarter earlier.
Buyers outnumbered sellers: 30 funds opened new BVS positions and 18 closed out — a net gain of 12 holders — while 57 added to existing stakes and 46 trimmed.
The largest buyer was Hillsdale Investment Management, adding an estimated $3.36M. The largest seller was Buckley Capital Advisors, cutting an estimated $2.71M.
- 157 institutional investors held Bioventus (BVS) as of Q1 2026, up from 148 in Q4 2025.
- Funds reported $466M of Bioventus stock for Q1 2026, up 25% quarter-over-quarter.
- 30 funds opened new Bioventus positions in Q1 2026 and 18 closed out, a net change of +12 holders.
- The largest Bioventus buyer in Q1 2026 was Hillsdale Investment Management, an estimated $3.36M added.
- The largest Bioventus seller in Q1 2026 was Buckley Capital Advisors, an estimated $2.71M sold.
Based on aggregated 13F filings for Q1 2026.